Monographs: Dosage forms: Specific monographs: Linezolid Tablets (Linezolidi compressi)

Category. Antituberculosis, antibiotic.

Storage. Linezolid tablets should be kept in an airtight container and protected from light.

Additional information. Strengths in the current WHO Model List of Essential Medicines (EML): 400 mg, 600 mg. Strengths in the current EML for children: 400 mg, 600 mg.

Requirements

Comply with the monograph for Tablets.

Definition. Linezolid tablets contains not less than 90.0% and not more than 110.0% of the amount of Linezolid (C16H20FN3O4) stated on the label.

Identity tests

  • Either tests A and C or tests B and C may be applied.

  1. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using the conditions given under "Assay". The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to linezolid in the chromatogram obtained with solution (2).

  2. Carry out as described under 1.14.1 Chromatography, Thin-layer chromatography, using silica gel R6 as the coating substance and a freshly prepared mixture of acetone R, toluene R and glacial acetic acid R (45:45:10 V/V/V) as the mobile phase. Apply separately to the plate 2 µL of each of the following two solutions. For solution (A), transfer a quantity of the powdered tablets, nominally containing 100 mg of Linezolid, to a flask and add 20 mL of methanol R. Stopper the flask and sonicate for 5 minutes, filter the suspension and use the clear supernatant. For solution (B), use a solution containing 5 mg of linezolid RS per mL. After removing the plate from the chromatographic chamber, allow it to dry in air or in a current of air. Examine the plate under ultraviolet light (254 nm). Spray the plate with basic potassium permanganate (~5 g/L) TS and examine the plate in daylight. The principal spot in the chromatogram obtained with solution (A) corresponds in position, appearance and intensity with the spot due to linezolid in the chromatogram obtained with solution (B).

  3. Transfer a quantity of the powdered tablets, nominally containing 25 mg of Linezolid, to a 50 mL volumetric flask, add 40 mL of methanol R and sonicate for 5 minutes. Dilute to volume with methanol R and mix. Filter the suspension and dilute 2 mL of the filtrate to 100 mL with methanol R. Record an adsorption spectrum of the solution in the range from 200 nm to 400 nm as described under 1.6 Spectrophotometry in the visible and ultraviolet regions. The spectrum exhibits a maximum at 258 nm.

    Alternatively, in combination with test A, where a diode-array detector is available, record the UV spectrum of the principal peak in the chromatograms with a diode array detector in the range of 200 nm to 400 nm. The UV spectrum of the principal peak in the chromatogram obtained with solution (1) corresponds to the UV spectrum of the peak due to linezolid in the chromatogram obtained with solution (2).

Dissolution. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms, using as the dissolution medium 900 mL of dissolution buffer, pH 6.8, TS and rotating the paddle at 50 revolutions per minute. At 30 minutes, withdraw a sample of about 10 mL of the medium through an in-line filter. Allow the filtered sample to cool to room temperature. Dilute 1.0 mL of this solution to 50.0 mL with the dissolution buffer.

Measure the absorbance as described under 1.6 Spectrophotometry in the visible and ultraviolet regions of the resulting solution in a cuvette with an optical pathlength of 10 mm at the maximum at about 251 nm, using the dissolution buffer as the blank.

For each of the tablets tested, calculate the total amount of linezolid (C16H20FN3O4) in the medium using the absorptivity value of 56.0 for linezolid (). Evaluate the results as described under 5.5 Dissolution test for solid oral dosage forms, Acceptance criteria. The amount of linezolid released is not less than 80% (Q) of the amount declared on the label.

Related substances. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm), packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (3.5 μm).

Use the following conditions for gradient elution:

  • mobile phase A: 90 volumes of phosphate buffer and 10 volumes of methanol R.
  • mobile phase B: 30 volumes of phosphate buffer, 50 volumes of acetonitrile R and 20 volumes of methanol R.

Prepare the phosphate buffer by dissolving 1.36 g of potassium dihydrogen phosphate R in 1000 mL of water R.

Time
(minutes)

Mobile phase A
(% V/V)

Mobile phase B
(% V/V)

Comments

0–2

100

0

Isocratic

2–10

100 to 75

0 to 25

Linear gradient

10–15

75

25

Isocratic

15–30

75 to 20

25 to 80

Linear gradient

30–35

20

80

Isocratic

35–36

20 to 100

80 to 0

Return to initial composition

36–40

100

0

Re-equilibration

Operate with a flow rate of 1.2 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm. Maintain the column temperature at 25 °C.

Use a mixture of 80 volumes of phosphate buffer and 20 volumes of acetonitrile R and as diluent. For solution (1), transfer a quantity of the powdered tablets, nominally containing 80.0 mg of linezolid, into a 100 mL volumetric flask, add 50 mL of phosphate buffer, sonicate for 5 minutes with intermediate shaking, add 20 mL of acetonitrile R, and sonicate for further 10 minutes with intermediate shaking. Allow the flask to cool to room temperature, dilute to volume with phosphate buffer, mix and filter. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL with diluent. For solution (3), dilute 1.0 mL of solution (2) to 10.0 mL with diluent. For solution (4), dissolve 5.0 mg each of linezolid RS, linezolid impurity A RS and linezolid impurity D RS and dilute to 100.0 mL with diluent.

Inject 10 µL each of solutions (1), (2), (3) and (4).

Use the chromatogram obtained with solution (4) to identify the peaks due to linezolid, impurity A and impurity D in the chromatogram obtained with solution (1). The impurity peaks, if present, are eluted at the following relative retention times with reference to linezolid (retention time about 17 minutes): impurity G about 0.49; impurity C about 0.59; impurity H about 0.75; impurity F about 0.80; impurity J about 1.28; impurity D about 1.36; impurity B about 1.42; impurity A about 1.50; impurity K about 1.53 and impurity I about 1.66.

The test is not valid unless in the chromatogram obtained with solution (4) the resolution between the peak of impurity D and the peak of impurity A is greater than 15.0. Also, the test is not valid unless in the chromatogram obtained with solution (3) the peak due to linezolid is detected with a signal-to-noise ratio of at least 20.

In the chromatogram obtained with solution (1):

  • the area of any peak corresponding to impurity G, when multiplied by a correction factor of 2.2, is not greater than three times the area of the peak due to linezolid in the chromatogram obtained with solution (3) (0.3%);

  • the area of any peak corresponding to linezolid related impurity C is not greater than twice the area of the peak due to linezolid in the chromatogram obtained with solution (3) (0.2%);

  • the area of any peak corresponding to impurity F is not greater than 3 times the area of the peak due to linezolid in the chromatogram obtained with solution (3) (0.3%);

  • the area of any other impurity peak is not greater than 1.7 times the area of the peak due to linezolid in the chromatogram obtained with solution (3) (0.17%).

  • The sum of the area of all impurity peaks is not greater than the area of the peak due to linezolid in the chromatogram obtained with solution (2) (1.0%). Disregard any peak with an area less than 0.5 times the area of the peak due to linezolid in the chromatogram obtained with solution (3) (0.05%).

Assay. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm), packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (3.5 μm).

Use the following conditions for gradient elution:

  • mobile phase A: 70 volumes of phosphate buffer, 15 volumes of acetonitrile R and 15 volumes of methanol R.
  • mobile phase B: acetonitrile R.

Prepare the phosphate buffer by dissolving 1.36 g of potassium dihydrogen phosphate R in 1000 mL of water R.

Time
(minutes)

Mobile phase A
(% V/V)

Mobile phase B
(% V/V)

Comments

0–7

100

0

Isocratic

7–9

10

90

Linear gradient

9–15

10

90

Isocratic

15–16

100

0

Return to initial composition

16–20

100

0

Re-equilibration

Operate at a flow rate of 1.2 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm. Maintain the column temperature at 25 °C.

Use a mixture of 80 volumes of phosphate buffer and 20 volumes of acetonitrile R and as diluent. For solution (1), weigh and powder 20 tablets. Transfer a quantity of the powdered tablets, nominally containing 240.0 mg of linezolid, into a 200 mL volumetric flask, add 100 mL of phosphate buffer and sonicate for 5 minutes. Add 40 mL of acetonitrile R and sonicate for 10 minutes. Allow the solution to cool to room temperature, make up to volume with phosphate buffer, mix and filter. Dilute 5.0 mL of this solution to 50.0 mL with the diluent . For solution (2), dissolve 60.0 mg of linezolid RS in a 50 mL volumetric flask in 30 mL of the diluent and sonicate for 5 minutes. Allow the solution to cool to room temperature and make up to volume with the diluent. Dilute 5.0 mL of this solution to 50.0 mL with the diluent.

Inject 10 μL each of solutions (1) and (2).

Measure the areas of the peaks corresponding to linezolid obtained in the chromatograms of solutions (1) and (2) and calculate the percentage content of linezolid (C16H20FN3O4) using the declared content of C16H20FN3O4 in linezolid RS.

Impurities. The impurities limited by the requirements of this monograph include those listed in the monograph on Linezolid, with the exception of impurity E.

to previous sectionto next section